Keyphrases
Confidence Interval
100%
P185HER2
36%
Normality Assumption
36%
School Satisfaction
36%
Stereotactic Body Radiation Therapy
36%
Chip Surface
36%
Metastatic Non-small Cell Lung Cancer
36%
Regulatory Relationship
36%
Siegel-Tukey
36%
Levene's Test
36%
Test for Scale
36%
Asian Ginseng
36%
Pembrolizumab
36%
Panax Ginseng
36%
Ethanol Toxicity
36%
Oryzias Latipes
36%
Rice-crayfish
36%
5-hydroxymethylcytosine (5hmC)
36%
Accelerated nursing Students
36%
Primary Central Nervous System Lymphoma (PCNSL)
36%
Cancer Genes
36%
Two-sample Location Problem
36%
Cell-free DNA (cfDNA)
36%
Empirical Distribution Function
36%
Cancer Risk Perception
36%
Among Us
36%
Oncolytic Viral Therapy
36%
Immunotherapy Response
36%
Microarray Data
36%
Bioinformatics
36%
Texas Cancer Registry
36%
Tumor Growth Kinetics
36%
Lung Cancer
36%
Edge Detection
36%
Detection Method
36%
Nonparametric Likelihood Ratio
36%
Drug Literature
36%
Information Evaluation
36%
Rank-based Test
36%
Literature Evaluation
36%
Blended Learning Environment
36%
On-road Driving
36%
Power Function
36%
Phase II Study
36%
Statistical Methods
36%
Clinical Data
36%
In Situ
36%
Divergence Loss
36%
Older Patients
36%
Time-course Gene Expression
36%
Medicine and Dentistry
Neoplasm
77%
Brain Metastasis
72%
Cancer Registry
72%
Overall Survival
54%
Phosphotransferase
36%
Breast Cancer
36%
Stereotactic Body Radiation Therapy
36%
Adolescence
36%
Non Small Cell Lung Cancer
36%
Immunotherapy
36%
Antithrombin III
36%
Primary Central Nervous System Lymphoma
36%
Burkitt's Lymphoma
36%
Neonatal Extracorporeal Membrane Oxygenation
36%
Oncolytic Virotherapy
36%
Endothelin 1
36%
Extracorporeal Membrane Oxygenation
36%
Statistical Analysis
36%
Lung Cancer
36%
Malignant Neoplasm
36%
5 Hydroxymethylcytosine
36%
Lung Carcinoma
36%
Course Evaluation
36%
Cell-Free DNA
36%
Angiogenesis
36%
Pembrolizumab
36%
Matrix Metalloproteinase
36%
Urinary System
36%
Natriuresis
36%
Tissue Inhibitor of Metalloproteinase 1
36%
Progression Free Survival
35%
Immune Checkpoint Inhibitor
34%
Gene Therapy
32%
Trastuzumab
29%
Disease Specific Survival
27%
Retainer
27%
Systemic Therapy
25%
Diseases
23%
Breast Cancer Cell Line
21%
Tumor Model
21%
Triple Negative Breast Cancer
21%
Mouse Mammary Tumor Virus
21%
Cancer Immunization
18%
Gene Expression
18%
Medicine
18%
DNA Microarray
18%
Sodium Excretion
18%
Cancer Therapy
18%
Odds Ratio
15%
Survival Rate
14%
